First Human Trial of Monoclonal Antibody to Prevent Malaria Opens | NIH: National Institute of Allergy and Infectious Diseases

First Human Trial of Monoclonal Antibody to Prevent Malaria Opens | NIH: National Institute of Allergy and Infectious Diseases

Monday, January 27, 2020 First Human Trial of Monoclonal Antibody to Prevent Malaria Opens A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial, sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 years old who have never had malaria. After receiving mAb CIS43LS, most of the volunteers will be exposed to malaria parasite-carrying mosquitoes under carefully controlled conditions at the Walter Reed National Military Medical Center in Bethesda to assess the ability of the mAb to confer protection from malaria infection.